Rami S Komrokji

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. doi request reprint Deletion 5q MDS: molecular and therapeutic implications
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA Electronic address
    Best Pract Res Clin Haematol 26:365-75. 2013
  2. doi request reprint Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome
    Rami S Komrokji
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Blood 120:3419-24. 2012
  3. doi request reprint Prognostic factors and risk models in myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Electronic address
    Clin Lymphoma Myeloma Leuk 13:S295-9. 2013
  4. doi request reprint Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes
    Rami S Komrokji
    Department of Hematological Malignancies, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Br J Haematol 162:517-24. 2013
  5. doi request reprint Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Am J Hematol 87:1006-9. 2012
  6. ncbi request reprint Advances in the management of myelofibrosis
    Rami S Komrokji
    Department of Malignant Hematology at the H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33617, USA
    Cancer Control 19:4-15. 2012
  7. ncbi request reprint Lenalidomide for treatment of myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Curr Pharm Des 18:3198-203. 2012
  8. doi request reprint Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Cancer 118:2659-64. 2012
  9. doi request reprint Outcome of patients with myelodysplastic syndromes in the Veterans Administration population
    Rami S Komrokji
    Department of Hematologic Malignancies, H Lee Moffitt Cancer and Research Institute, Tampa, FL 33612, USA
    Leuk Res 34:59-62. 2010
  10. doi request reprint Role of lenalidomide in the treatment of myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Semin Oncol 38:648-57. 2011

Collaborators

Detail Information

Publications27

  1. doi request reprint Deletion 5q MDS: molecular and therapeutic implications
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA Electronic address
    Best Pract Res Clin Haematol 26:365-75. 2013
    ..The integrated effects of haploinsufficiency for these key genes, in aggregate, lead to the full phenotype of the disorder. ..
  2. doi request reprint Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome
    Rami S Komrokji
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Blood 120:3419-24. 2012
    ..The benefits of lenalidomide plus rhu-EPO are currently under investigation in a phase 3 Eastern Cooperative Oncology Group (ECOG)-sponsored intergroup study. This study is registered at www.clinicaltrials.gov as NCT00910858...
  3. doi request reprint Prognostic factors and risk models in myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Electronic address
    Clin Lymphoma Myeloma Leuk 13:S295-9. 2013
    ..We are learning more about the biology of the disease by uncovering the various genetic and molecular mutations. Those in turn, serve as prognostic factors and will be incorporated in the new risk models. ..
  4. doi request reprint Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes
    Rami S Komrokji
    Department of Hematological Malignancies, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Br J Haematol 162:517-24. 2013
    ..In addition, four patients each achieved transfusion independence and haematological improvements. In conclusion, oral rigosertib is bioavailable and well tolerated, and has clinical activity in patients with MDS. ..
  5. doi request reprint Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Am J Hematol 87:1006-9. 2012
    ..8; 95% CI 0.6-0.9; P = 0.004). Our findings indicate that hypoalbuminemia is an independent prognostic biomarker that may serve as a surrogate representative of disease biology or comorbidities in patients with MDS...
  6. ncbi request reprint Advances in the management of myelofibrosis
    Rami S Komrokji
    Department of Malignant Hematology at the H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33617, USA
    Cancer Control 19:4-15. 2012
    ..Of the MPNs, MF presents with the most severe morbidity and greatest mortality. Although the cause of MF is unknown, it is thought to occur from acquired mutations that target the hematopoietic stem cell...
  7. ncbi request reprint Lenalidomide for treatment of myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Curr Pharm Des 18:3198-203. 2012
    ..We highlight the mechanism of action and the recent advances in understanding the biology of del (5q) MDS. We also explore its potential use and the efforts to further improve its activity in non-del (5q) MDS...
  8. doi request reprint Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Cancer 118:2659-64. 2012
    ..We applied the MDAS to Moffitt Cancer Center (MCC) MDS patients to validate its prognostic utility...
  9. doi request reprint Outcome of patients with myelodysplastic syndromes in the Veterans Administration population
    Rami S Komrokji
    Department of Hematologic Malignancies, H Lee Moffitt Cancer and Research Institute, Tampa, FL 33612, USA
    Leuk Res 34:59-62. 2010
    ..MDS became reportable to the Surveillance, Epidemiology, and End Results Program (SEER) in 2001. We report first study of MDS among large population in the Veteran Affair system...
  10. doi request reprint Role of lenalidomide in the treatment of myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Semin Oncol 38:648-57. 2011
    ..Finally, we highlight the current understanding of its mechanism of action, discussing the emerging insight into the underlying biology of del(5q) MDS and its linkage to potential targets of lenalidomide...
  11. doi request reprint Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data
    Rami S Komrokji
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Clin Lymphoma Myeloma Leuk 11:257-60. 2011
    ..Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) outcome in the United States has not been reported outside the context of clinical trials...
  12. doi request reprint Management of lower-risk myelodysplastic syndromes: the art and evidence
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, FOB 3rd Floor, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Curr Hematol Malig Rep 6:145-53. 2011
    ..We use a case-based format to discuss current options for treatment, including erythropoiesis-stimulating agents, hypomethylating agents, lenalidomide, immunosuppressive therapy, supportive care, and investigational agents...
  13. doi request reprint Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions
    Rami S Komrokji
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Hematol Oncol Clin North Am 24:377-88. 2010
    ....
  14. doi request reprint Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Curr Hematol Malig Rep 5:9-14. 2010
    ..This article reviews the clinical experience with lenalidomide, highlighting recent understanding of the dual karyotype-dependent mechanisms of action...
  15. doi request reprint Myelodysplastic syndromes classification and risk stratification
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Hematol Oncol Clin North Am 24:443-57. 2010
    ..This article reviews MDS classification and risk stratification highlighting differences between the various systems...
  16. doi request reprint Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
    Asmita Mishra
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Am J Hematol 88:566-70. 2013
    ..Our data validate the prognostic value of the proposed IPSS-R and show that its refined IPSS prognostic discrimination can be applied to actively treated patients...
  17. doi request reprint Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome
    Celeste Bello
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer 117:1463-9. 2011
    ..The authors evaluated predictive factors in patients with secondary AML treated with anthracycline-based induction therapy...
  18. doi request reprint Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis
    Mohamed A Kharfan-Dabaja
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center, Tampa, FL, USA Department of Oncologic Sciences, H Lee Moffitt Cancer Center University of South Florida College of Medicine, Tampa, FL, USA
    Br J Haematol 163:315-25. 2013
    ..Addition of GO to conventional chemotherapy as induction therapy may improve relapse-free and event-free survival, but does not impact overall survival and significantly increases early mortality in AML. ..
  19. doi request reprint Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models
    Vu H Duong
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Leuk Res 37:510-5. 2013
    ..Response rates were comparable to those reported for de novo myelodysplastic syndrome. When we analyzed outcomes according to five scoring systems, only the Global MD Anderson Risk Model predicted survival with statistical significance...
  20. doi request reprint Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature
    Rahel A Mathew
    University of South Florida, School of Medicine, Tampa, FL, USA
    Leuk Res 36:72-80. 2012
    ..8 months. Overall survival from diagnosis to the last follow-up in patients with LC was 28.2 months, shorter than patients without LC (44 months). LC and its equivalent could predict disease progression to AML...
  21. pmc TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients
    Gisela Caceres
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612
    Proc Natl Acad Sci U S A 110:16127-32. 2013
    ..We conclude that targeted suppression of p53 could support effective erythropoiesis in lenalidomide-resistant del(5q) MDS. ..
  22. doi request reprint Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens
    Samantha L Price
    Department of Pharmacy, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Leuk Res 35:301-4. 2011
    ..2% for MEC (P=0.09), with median OS of 11 and 4.5 months, respectively (P=0.07). In first relapse, CR was 36.8% and 25.9% (P=0.35) and median OS was 6.7 and 6.7 months, respectively (P=0.87). Our data support use of CLAG for RR-AML...
  23. pmc Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome
    Adam W Mailloux
    Immunology Department, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Immunol 189:3198-208. 2012
    ..Based on these findings, Treg(EM) cell expansion may be synonymous with human Treg activation and indicate microenvironmental changes conducive to transformation in myelodysplastic syndromes...
  24. doi request reprint Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome
    Mohamed A Kharfan-Dabaja
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Biol Blood Marrow Transplant 17:384-93. 2011
    ..These results support day 90 hypoalbuminemia as an adverse prognostic marker for NRM and OS after allo-HCT for acute myelogenous leukemia and myelodysplastic syndrome...
  25. doi request reprint Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
    Amer M Zeidan
    aDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland bDepartment of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute cDepartment of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Curr Opin Hematol 21:123-30. 2014
    ..Azacitidine prolongs survival by a median of only 9.5 months. Failure of HMA therapy is associated with a very dismal prognosis. Therefore, novel therapeutic approaches are clearly needed...
  26. doi request reprint GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
    Eric Padron
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Blood 121:5068-77. 2013
    ..These preclinical data indicate that GM-CSF signaling inhibitors merit further investigation in CMML and that GM-CSFR expression on myeloid progenitors may be a biomarker for this therapy...
  27. doi request reprint Myelodysplastic syndromes
    Rafael Bejar
    From the Division of Hematology and Oncology, Moores Cancer Center, University of California, San Diego Cleveland Clinic Taussig Cancer Institute, Cleveland, OH H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    Am Soc Clin Oncol Educ Book 2013:256-70. 2013
    ..classify and risk stratify MDS, tailoring treatment accordingly? How do we diagnose and manage the challenging group of patients with MDS/myeloproliferative neoplasms (MPN) overlap? And finally, what is on the horizon for novel therapies?..